Problem

Axiom Bio addresses unexpected human drug toxicity, particularly liver injury, that can derail medicines late in development or after substantial research and clinical investment. The pain is both scientific and economic: traditional physical experiments are costly, while toxicity remains an unsolved problem that can cost the industry billions. Axiom reports an estimated cost of $100–$450 per compound for its approach versus $3,000–$15,000 for physical experiments.

The main use case is early screening of pharmaceutical and biotech candidates before they enter or advance through clinical trials. By identifying liver-risk signals, explaining their biological causes, and suggesting how to engineer toxicity out of a molecule, Axiom aims to help developers make earlier go/no-go decisions and avoid failures such as drug-induced liver injury.

Product / Service

Axiom combines proprietary human-cell experimentation with AI models and an agentic software layer that translates experimental data into human clinical risk. Its platform measures drug exposure, metabolism, cellular biology, and clinical outcomes using primary human hepatocytes and multi-cell hepatic systems, with modalities including imaging, transcriptomics, proteomics, and mass spectrometry. The Translate offering is described as an end-to-end service, from data generation for a customer’s molecules through AI reasoning and clinical risk assessment.

The product compares compounds across assays and toxicity endpoints, summarizes complex human-relevant data, identifies structure-toxicity relationships, and explains the mechanisms behind predicted risk. Axiom reports roughly 70–75% sensitivity for identifying toxic compounds and about 90% accuracy or specificity for identifying safe ones, at substantially lower cost than physical assays. The intended benefit is faster, more interpretable toxicity assessment that lets scientists advance promising medicines while redesigning or abandoning risky ones earlier.

Market

Axiom competes in AI-enabled in-silico drug safety, predictive toxicology, and enterprise biotechnology software for pharmaceutical and biotech R&D. Tracxn identifies four active competitors, including Stemina Biomarker Discovery, NeuTherX, and Celesc. The broader competitive set includes conventional animal and laboratory toxicity testing, which Axiom is seeking to replace or reduce with human-relevant experimental data and predictive models.

The company has meaningful early traction but its revenue scale is not established in the available evidence. Axiom announced $15 million in seed funding in April 2025 and reported a dataset spanning more than 130,000 molecules, including over 700 clinical-stage compounds, alongside pilot studies with six of the top twenty pharmaceutical companies, a major agrochemical company, biotechnology firms, and other partners. Its official site was still publishing research in March 2026, supporting that it remained active; however, no reliable revenue figure or definitive evidence that it is formally pre-revenue was disclosed, so the best characterization is an early commercial and pilot-stage company with substantial technical and customer validation.